Combined modality treatment of stage III and inflammatory breast cancer. M.D. Anderson Cancer Center experience.
Seven hundred fifty-two patients with stage III disease (of those, 178 patients with inflammatory carcinoma) were treated with a combined modality approach at our institute in seven prospective studies. After three to four cycles of chemotherapy, each patient was treated with local therapy. An estimated 54% of patients with stage IIIA disease and 24% of patients with stage IIIB disease were free of disease. An estimated 30% of patients with inflammatory carcinoma of breast were free of disease beyond 10 years with this approach.
University of Texas M.D. Anderson Cancer Center, Houston, USA.
A U
AU
Buzdar
S E
SE
Singletary
D J
DJ
Booser
D K
DK
Frye
B
B
Wasaff
G N
GN
Hortobagyi
D000230:Adenocarcinoma / Q000473:pathology / Q000628:therapy*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D001943:Breast Neoplasms / Q000473:pathology / Q000628:therapy*; D003131:Combined Modality Therapy; D018572:Disease-Free Survival; D005260:Female; D006801:Humans; D009367:Neoplasm Staging